G

ood morning, everyone. Damian Garde here, filling in for Ed Silverman with your requisite helping of headlines about the drug business. Here’s hoping they propel you into and through all that stands between you and the weekend.

The FDA’s latest approval, a drug for a symptom of Parkinson’s disease, is drawing a bit of a controversy, STAT tells us. Made by Adamas Pharmaceuticals (ADMS), the drug is an extended-release version of the generic amantadine, meant to address the involuntary spasms that sometimes result from treating Parkinson’s. But a month’s supply of regular amantadine goes for about $45, and thus Adamas’s previously disclosed plan to charge between $10,000 and $30,000 a year for its reformulated drug is already attracting criticism.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy